Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2007, Pages 249-256

  Hogan, D ^a   Pratha, V ^a   Riff, D ^b   Ducker, S ^b   Schwartz, H ^c   Soffer, E ^d   Wang, W ^d   Rath, N ^d   Comer, G M ^d  

^a Clinical Applications Laboratories   (United States)

^b Advanced Clinical Research Institute   (United States)

^c MIAMI RESEARCH ASSOCIATES   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PANTOPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG GRANULE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; STATISTICAL ANALYSIS; STEADY STATE; STUDENT T TEST; TABLET; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; ESOPHAGITIS; FEMALE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED;

EID: 34250837382     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03375.x     Document Type: Article

References (14)

1. Hirschowitz BI, Simmons J, Mohnen J. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Aliment Pharmacol Ther 2001 15 : 1785 806.
2. Jensen RT, Metz DC, Koviack PD, et al. Prospective study of the long-term efficacy and safety of lansoprozole in patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993 7 (Suppl. 1 597 610.
3. Metz DC, Pisegna JR, Fishabeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison Syndrome are too high. Gastroenterology 1992 103 : 1498 508.
4. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome: a prospective nine-year study on efficacy and safety. Aliment Pharmacol Ther 1993 7 : 597 610.
5. Metz DC, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In : Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Frontiers in Gastrointestinal Research. Basal : Karger, 1995 : 240 57.
6. Feldman M. Gastric secretion: normal and abnormal. In : Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Diseases, Philadelphia : W.B. Saunders, 1998 : 587 603.
7. Mason MC, Giles GR, Clark CG. Continuous intravenous pentagastrin as a stimulant of maximal gastric acid secretion. Gut 1969 10 : 34 8.
8. Pisegna JR, Martin P, McKeand W, Ohing G, Walsh JH, Paul J. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose response study. Am J Gastroenterol 1999 94 : 2874 80.
9. Pratha VS, Hogan DL, Lane JR, et al. Inhibition of pentagastrin- stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults. Dig Dis Sci 2006 51 : 123 31.
10. Metz DC, Pratha V, Martin P, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 2000 95 : 626 33.
11. Reynolds JR, Walt RP, Hardcastle JD, Clark AG, Smart HL, Langman MJ. 24-hour intragastric pH: continuous monitoring or nasogastric aspiration? Digestion 1999 33 : 219 24.
12. Hunyady B, Cziraki A, Vincze A, et al. Testing the acid-binding capacity of Tisacid suspension and tablets by intragastric pH determination in patients with hyperacidity. Orv Hetil 1994 135 : 53 6.
13. Kushner I, Rapp W, Burtin P. Electrophoretic and immunochemical demonstration of the existence of four human pepsinogens. J Clin Investigation 1964 43 : 1983 93.
14. Feston JW, Pilmer BL, Chiu YL, et al. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole. Aliment Pharmacol Therap 2004 19 : 1111 22.